Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Cisplatin vs. AC in BRCA-Mutated Breast Cancer
NCT01670500Phase 2Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Oct 2012
- Primary completion
- May 2019
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Cisplatin micelle injection (HA132) in breast cancer, sponsored by Beth Israel Deaconess Medical Center. Started Oct 2012; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01670500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01670500.